Wird geladen...
PD-L1 in melanoma: facts and myths
The use of monoclonal antibodies that block immunologic checkpoints that would otherwise mediate the adaptive immune resistance have paved the way in cancer treatment. There is evidence that blocking the PD-1/PD-L1 axis is a strategy of overriding importance in the treatment of patients with metasta...
Gespeichert in:
| Veröffentlicht in: | Melanoma Manag |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Future Medicine Ltd
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6096437/ https://ncbi.nlm.nih.gov/pubmed/30190888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/mmt-2016-0013 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|